Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01764451 · ClinicalTrials.gov registry record · Early Phase 1
Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
A Early Phase 1 study, sponsored by University of New Mexico.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT01764451 is a Early Phase 1 study that was terminated before completion, run by University of New Mexico. The registered enrollment target is 12 participants.
The verdict
NCT01764451, a Early Phase 1 study, was terminated before completion, sponsored by University of New Mexico.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. In some patients, CCMs affect the blood brain barrier (BBB). The BBB is the body's separation of blood and its contents in the brain from the brain tissue itself. Abnormal leakiness or permeability of this barrier can cause disease. We will measure the permeability (leakiness) of the BBB using a magnetic resonance imaging (MRI) technique called dynamic contrast-enhanced MRI (DCEMRI). The purpose of this study is to look at whether statin medications change the permeability (leakiness) of the blood brain barrier in CCM patients. Statin medications are used to lower cholesterol levels and prevent heart attack and stroke. In addition, this medication may decrease the risk of brain hemorrhage or bleeding in patients with CCM. This study will examine whether the permeability of the BBB changes following the administration of simvastatin for three months.
Interventions
- DRUG Simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-03 |
| Est. Completion | 2016-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01764451
The ClinicalTrials.gov registry entry for NCT01764451 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Simvastatin is the first listed.
NCT01764451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01764451 about?
NCT01764451 is a clinical study titled "Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins". Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. In some patients, CCMs affect the blood brain barrier (BBB). The BBB is the body's separation of blood and its contents in the brain from ...
What is the current status of trial NCT01764451?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2012-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01764451?
The interventions under investigation include: Simvastatin (DRUG).
Who is sponsoring clinical trial NCT01764451?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.